ALK and anaplastic large cell lymphoma: Analysis of crizotinib pharmacokinetics in the COG study suggested that at the pediatric maximum tolerated dose, free crizotinib plasma levels exceed those required for in vitro killing of NPM-ALK–rearranged anaplastic large-cell lymphoma (ALCL) cells.43